CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio ...

Learn how gene therapy is revolutionising the treatment of haemophilia a genetic disorder that affects blood clotting ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

Abeona Therapeutics Inc.’s ABEO share price has surged by 6.60%, which has investors questioning if this is right time to ...

New solutions support high-precision analytics for process development, batch release, and regulatory compliance.

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

Molecular biology has transitioned to a new era where precise genetic manipulation plays a critical role in research, medicine, and biotechnology. Among the vital tools in this field are cloning ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...

EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals (Patent Application No. 19/191,246) ...